An update on drug combinations for treatment of myeloma

Expert Opinion on Investigational Drugs

Volumn 17, Issue 1, 2008, Pages 1-12

  Srikanth, Muralikrishnan ^a   Davies, Faith E ^a   Morgan, Gareth J ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Bortezomib; Cyclophosphamide; Dexamethasone; Lenalidomide; Melphalan; Myeloma; Novel therapies; Refractory disease; Relapsed disease; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; ANTHRACYCLINE DERIVATIVE; BORTEZOMIB; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PERIFOSINE; PREDNISOLONE; PROTEASOME INHIBITOR; TANESPIMYCIN; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; PYRAZINE DERIVATIVE;

ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOLOGICAL THERAPY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; FATIGUE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; INFECTION; LONG TERM CARE; LOW DRUG DOSE; MICROENVIRONMENT; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA CELL; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OUTCOMES RESEARCH; PATHOGENESIS; PERIPHERAL NEUROPATHY; RELAPSE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SURVIVAL TIME; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; RECURRENT DISEASE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 38949110767     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.1.1     Document Type: Review

References (66)

1. MacLennan IC, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The medical research council working party for leukaemia in adults. Lancet 1992;25:200-5
2. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996;335:91-7
3. Child JA, Morgan q, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83
4. Blade J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard conventional chemotherapy in multiple myeloma patients responding to initial treatment chemotherapy: long term results from a prospective randomised trial from the Spanish cooperative group PETHEMA. Blood 2005; 106:3755-9
5. Barlogie B, Kyle, RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma. Final results of the Phase III US Intergroup trial S9321. J Clin Oncol 2006;24:929-36
6. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1060-73
7. Singhal S, Mehra J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71
8. Palumbo A, Bertola A, Falco P, et al. Efficacy of low dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Haematol J 2004;5:318-24
9. Sidra G, Williams CD, Russell NH, et al. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica 2006;91:862-63
10. Dimopoulos MA, Hamilos G, Zomas A, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with myeloma. Haematol J 2004;5:112-17
11. Garcia-Sanz R, Gonzalez-Porras Jr, Hernandez JM, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma patients. Leukemia 2005;18:856-63
12. Kropff MH, Lang N, Bisping G, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003;122:607-16
13. Kyriakou C, Thomson K, D'sa S, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 2005;129:763-70
14. Lee CK Barlogie B, Munshi N, et al. DTPACE: an effective novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003;21:2732-39
15. Palumbo A, Avonto I, Bruno B, et al. Intravenous melphalan, thalidomide and prednisolone in refractory and relapsed myeloma. Eur J Haematol 2006;76:273-77
16. Hussein MA, Baz R, Srkalovic: G, et al. Phase II study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 2006;81:889-95
17. Rajkumar SV, Blood E, Vesole DH, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with doxamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern cooperative oncology group. J Clin Oncol 2006;24:431-6
18. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide and dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319-23
19. Weber D, Rankin Y, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated myeloma. J Clin Oncol 2003;21:16-19
20. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dommethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35-9
21. Wu P, Davies FE, Horton C, et al. The combination of cyclophosphamide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide-vincristine-doxorubicin-methylprednisolone as induction chemotherapy prior to autolgous transplantation for multiple myeloma: a case matched analysis, Leuk Lymphoma 2006;47:2335-9
22. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised. controlled trial. Lancet 2006;367:825-31
23. Facon T, Mary J, Harousseau J, et al. Superiority of melphalan - prednisolone + thalidomide over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. J Clin Oncol 2006;24:A1
24. Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients treated with thalidomide. Patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006;24:4507-14
25. Rajkumar SV. Thalidomide therapy and deep vein thrombosis in myeloma. Mayo Clin Proc 2005;80:1549-51
26. Breikreutz I, Lokhorst HM, Raab MS, et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 2007;21:1294-9
27. Barlogie B, Tricot G, Rasmussen E, et al. Thalidomide and hematopoiedc cell transplantation in myeloma. N Engl J Med 2006;354:1021-30
28. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signalling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells. Therapeutic implications. Blood 2002;99:4525-30
29. Richardson PG, Blood E, Mitsiades CS, et al. A randomized Phase II study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458-64
30. Weber DM, Chen C, Niesvezky R, et al. Lenalidomide plus high dose dexamethasone provides improved survival compared to high dose dexamethasone for relapsed, refractory myeloma. Results of a North American Phase III study. J Clin Oncol 2006;24:A427
31. Dimopoulos MA, Spencer A, Attal M, et al. Study of lenalidomide plus ducamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma. Results of a Phase III study (MM-010). Blood 2005;106:A6
32. Stadtmauer E, Weber D, Dimopolous M, et al. Lenalidomide in combination with dexamethasone is more effective than dexamethasone at first relapse in relapsed multiple myeloma. Blood 2006;108:A3552
33. Morgan GJ, Vu P, Davies FE, et al. Lenalidomide in combination with cyclophosphamide and dexamethasone is an effecEive and well tolerated regimen for myeloma patients. Br J Haematol 2007;137:268-9
34. Baz R, Walker E, Karam MA, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma safety and efficacy. Ann Oncol 2006;17:1766-71
35. Knop, S, Gerecke C, Topp MS, et al. Lenalidomide (Revlimid™), adriamycin and dexamethasone chemotherapy (RAD) is safe and effective in treatment of relapsed multiple myeloma - first results of a German multicenter Phase I/II trial. Blood 2006;108:A408
36. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050-3
37. Rajkumar SV, Jacobus S, Callander N, et al. A randomized Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide low dose dexamethasone in newly diagnosed multiple myeloma: a trial coordinated by the Eastern cooperative oncology group. Blood 2006;108:A799
38. Palumbo A, Falco P. Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA Italian multiple myeloma network. J Clin Oncol 2007;25(28):4459-65
39. Knight R, Delap RJ, Zeldis JB. Lenalidomide and venous thrombosis in myeloma. N Engl J Med 2006;354:2079-80
40. Zonder JA, Barlogie B, Durie BG, et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006;108:403
41. Kanagasabaphy P, Morgan GJ, Davies FE. Proteasome inhibition and multiple myeloma. Curr Opin Investig Drugs 2007;8:447-51
42. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6
43. Aghajanian C, Soignet S, Dizon DS, et al. A Phase I trial of the novel proteasome inhibitor PS341 in advanced and solid tumor malignancies. Clin Cancer Res 2002;8:2505-11
44. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-27
45. Richardson PG, Barlogie B, Berenson J, et al. A Phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17
46. Jagannath S, Barlogie B, Berenson J, et al. A Phase II study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127:165-72
47. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a Phase III trial in relapsed multiple myeloma; final time to event results of the APEX trial. Blood 2007;110(10):3557-60
48. Berenson JR, Yang HH, Sadler K. Phase I - II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006;24:937-44
49. Davies FE, WU P, Jenner MW, et al. The combination of cyclophosphamide, velcade and dexamethasone induces higher response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica 2007;92:1149-50
50. Reece DE, Piza GR, Trudel S, et al. A Phase I - II trial of bortezomib (Velcade) and oral cyclophosphamide plus prednisolone for relapsed/ refractory multiple myeloma. Blood 2005;106:A2556
51. Kropff M, Bisping G, Schuck E, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007;138:330-37
52. Morris TCM, Drake M, Kettle PJ, et al. Bortezomib, adriamycin dexamethasone (PAD) combination therapies or patients with relapsed or refractory myeloma previously treated with VAD or VAD like therapy. Blood 2007;108:5117
53. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized Phase III study of pegyl ated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma; combination therapy improves time to progression. J Clin Oncol 2007;25:3892-901
54. Palumbo AP, Ambrosini MT, Benevoto G, et al. Bortezomib, melphalan, prednisolone and thalidomide (VMPT) for relapsed multiple myeloma. Blood 2007;109:2767-72
55. Chanan-Khan A, Miller KC. Velcade, doxil thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma. Leuk Lymphoma 2005;46:1103-4
56. Richardson PG, Jagannath S Avigan D, et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter Phase I trial. Blood 2006;108:A405
57. Richardson PC, Chanan-Khan A, Lonial S, et al. A multicenter Phase I clinical trial of tanespimycin (KOS-953) + bortezomib (BZ): encouraging activity and manageable toxicity in heavily pre-treated patients with relapsed refractory multiple myeloma (MM). Blood 2006;108:A406
58. Richardson PC, Jakubowiak A, Wolf J, et al. A multicenter Phase I/lI trial of perifosine (KRX-0401) alone and in combination with bortezomib in relapsed and refractory myeloma patients previously treated with bortezomib: preliniary results. Haematologica 2006;91:1498-505
59. Popat R, Williams C, Cook M, et al. A Phase I/II srudy of bortezomib, low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma. Blood 2006;108:A3542
60. Zangari M, Barlogie B, Burns MJ, et al. VTD for advanced and refractory myeloma. Long term follow up of Phase I-II trial UARK-37. Superior outcomes in patients with normal cytogenetics and no T. Blood 2005;106:A716
61. Hollmig K, Stover J, Talamo G, et al. VATD is an effective regimen in patients with relapsed or refractory myeloma. Blood 2004;104:2399
62. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results. of an IFM Phase II study. Haematologica 2006;91:1498-505
63. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/ bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005;129:755-62
64. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisolone in elderly untreated patients with multiple myeloma. Results of a multicentre Phase I/Il study. Blood 2006;108:2165-72
65. Wang M, Giralt S, Delasalle K, et al. Bortezomib in combination with thalidomide and dexamethasone for previously untreated multiple myeloma. Hematology 2007;12:235-9
66. Barlogie B, Anaissie E, Van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma; early results of total therapy 3. Br J Haematol 2007;138:176-85